KV Pharmaceutical, Purdue Pharma settle painkiller patent dispute - Nashville Business Journal:

haygoodfoafyga1359.blogspot.com
Under the settlement, KV agreed to no longert disputethe “validity, enforceability or infringement” of the Purdued generic oxycodone patents. In return, Purduee granted KV a limited, non-exclusive license to manufacturewand sell, in the United States, a certaihn amount of various dosage strengthe of the drugs as long as KV pays royalties to KV also reached a deal to be an non-exclusive distributor in the Unitedx States of certain generic versions of OxyContin. These agreementd settle three patent infringementlawsuitsa Stamford, Conn.-based Purdue filed agains KV in 2007. KV still faces more lawsuits fromothetr companies, consumers and shareholders. Three individual s in St.
Clair County Circuit Court againstf KV, alleging that certain drugs contained a potentially lethal amount of morphinr due to oversized tablets that were eventually recalled by thepharmaceutical company. Last , a Florida-based dermatologty company, sued KV, of a patent for Duac topical gel, an acne KV also faces lawsuits from shareholders about manufacturing compliance andthe company’as financial prospects. Brentwood, Mo.-based KV has and recallex painkillers. In March, KV said it with the FDA that outline a series of measures that will permitg KV and its subsidiaries to resume manufacturingand distribution.